Hertz DL - Search Results

1

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.

Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Quintanilha JCF, et al. Among authors: hertz dl. Br J Cancer. 2022 Feb;126(2):265-274. doi: 10.1038/s41416-021-01557-w. Epub 2021 Oct 6. Br J Cancer. 2022. PMID: 34616010 Free PMC article. Clinical Trial.

2

Pharmacogenetics of breast cancer therapies.

Hertz DL, McLeod HL, Hoskins JM. Hertz DL, et al. Breast. 2009 Oct;18 Suppl 3:S59-63. doi: 10.1016/S0960-9776(09)70275-9. Breast. 2009. PMID: 19914545 Free article. Review.

3

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. Hertz DL, et al. Breast Cancer Res Treat. 2012 Jul;134(1):401-10. doi: 10.1007/s10549-012-2054-0. Epub 2012 Apr 18. Breast Cancer Res Treat. 2012. PMID: 22527101 Free PMC article.

4

Tamoxifen and CYP2D6: a contradiction of data.

Hertz DL, McLeod HL, Irvin WJ Jr. Hertz DL, et al. Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Oncologist. 2012. PMID: 22531359 Free PMC article. Review.

5

Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.

Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC. Hertz DL, et al. Br J Clin Pharmacol. 2012 Jul;74(1):197-200. doi: 10.1111/j.1365-2125.2012.04165.x. Br J Clin Pharmacol. 2012. PMID: 22680343 Free PMC article.

6

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. Hertz DL, et al. Ann Oncol. 2013 Jun;24(6):1472-8. doi: 10.1093/annonc/mdt018. Epub 2013 Feb 14. Ann Oncol. 2013. PMID: 23413280 Free PMC article.

7

Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Krens SD, McLeod HL, Hertz DL. Krens SD, et al. Among authors: hertz dl. Pharmacogenomics. 2013 Apr;14(5):555-74. doi: 10.2217/pgs.13.33. Pharmacogenomics. 2013. PMID: 23556452 Free PMC article.

8

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.

Hertz DL, McLeod HL. Hertz DL, et al. J Hum Genet. 2013 Jun;58(6):346-52. doi: 10.1038/jhg.2013.42. Epub 2013 May 16. J Hum Genet. 2013. PMID: 23677053 Review.

9

Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.

McWhinney-Glass S, Winham SJ, Hertz DL, Yen Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, McLeod HL; Scottish Gynaecological Clinical Trials Group. McWhinney-Glass S, et al. Among authors: hertz dl. Clin Cancer Res. 2013 Oct 15;19(20):5769-76. doi: 10.1158/1078-0432.CCR-13-0774. Epub 2013 Aug 20. Clin Cancer Res. 2013. PMID: 23963862 Free PMC article.

10

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL. Hertz DL, et al. Breast Cancer Res Treat. 2014 May;145(1):245-54. doi: 10.1007/s10549-014-2910-1. Epub 2014 Apr 6. Breast Cancer Res Treat. 2014. PMID: 24706167 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page